Amends GS 90-106(a3) (limiting prescriptions of targeted controlled substances for pain) to limit the supply of targeted controlled substances a physician may prescribe to a patient after an initial consultation for acute pain to a three-day (was, five-day) supply. Effective October 1, 2021.